Evidence map›Paper›PMID 39592523›Full record

ArticleDiscover oncology2024

Development of a novel centrosome-related risk signature to predict prognosis and treatment response in lung adenocarcinoma.

Ziqiang Wang, Chao Zuo, Jiaojiao Fei, Huili Chen, Luyao Wang, Yiluo Xie, Jing Zhang, Shengping Min, Xiaojing Wang, Chaoqun Lian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ziqiang WangAnhui Province Key Laboratory of Respiratory Tumor and Infectious Disease, Department of Pulmonary and Critical Care Medicine, Molecular Diagnosis Center, First Affiliated Hospital of Bengbu Medical University, Bengbu, 233030, China.
Chao ZuoDepartment of Clinical Laboratory, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.
Jiaojiao FeiAnhui Province Key Laboratory of Respiratory Tumor and Infectious Disease, Department of Pulmonary and Critical Care Medicine, Molecular Diagnosis Center, First Affiliated Hospital of Bengbu Medical University, Bengbu, 233030, China.
Huili ChenResearch Center of Clinical Laboratory Science, Bengbu Medical University, Bengbu, 233030, China.
Luyao WangDepartment of Genetics, School of Life Sciences, Bengbu Medical University, Bengbu, 233030, China.
Yiluo XieDepartment of Clinical Medicine, Bengbu Medical University, Bengbu, 233030, China.
Jing ZhangDepartment of Genetics, School of Life Sciences, Bengbu Medical University, Bengbu, 233030, China.
Shengping MinAnhui Province Key Laboratory of Respiratory Tumor and Infectious Disease, Department of Pulmonary and Critical Care Medicine, Molecular Diagnosis Center, First Affiliated Hospital of Bengbu Medical University, Bengbu, 233030, China.
Xiaojing Wang *Anhui Province Key Laboratory of Respiratory Tumor and Infectious Disease, Department of Pulmonary and Critical Care Medicine, Molecular Diagnosis Center, First Affiliated Hospital of Bengbu Medical University, Bengbu, 233030, China. wangxiaojing8888@163.com.
Chaoqun Lian *Research Center of Clinical Laboratory Science, Bengbu Medical University, Bengbu, 233030, China. lianchaoqun@bbmc.edu.cn.

Funding

Open Resesrch Fund Project of Anhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease HX2023D01Open Resesrch Fund Project of Anhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease HX2023D02the National Natural Science Foundation of China 82373329
6 · The paper itself

Abstract

backgroundAbnormalities of centrosomes, the major microtubular organizing centers of animal cells and regulators of cell cycle progression, usually accelerate tumor progression, but their prognostic value in lung adenocarcinoma (LUAD) remains insufficiently explored.

methodsWe collected centrosome genes from the literature and identified LUAD-specific centrosome-related genes (CRGs) using the single-sample gene set enrichment analysis (ssGSEA) algorithm and weighted gene co-expression network analysis (WGCNA). Univariate Cox was performed to screen prognostic CRGs. Consistent clustering was performed to classify LUAD patients into two subgroups, and centrosome-related risk score signatures were constructed by Lasso and multivariate Cox regression to predict overall survival (OS). We further explored the correlation between CRS and patient prognosis, clinical manifestations, mutation status, tumor microenvironment, and response to different treatments.

resultsWe constructed centrosome-associated prognostic features and verified that CRS could effectively predict 1-, 3-, and 5-year survival in LUAD patients. In addition, patients in the high-risk group exhibited elevated tumor mutational loads and reduced levels of immune infiltration, particularly of T and B cells. Patients in the high-risk group were resistant to immunotherapy and sensitive to 5-fluoropyrimidine and gefitinib. The key gene spermine synthase (SRM) is highly expressed at the mRNA and protein levels in LUAD. DISCUSSION: Our work develops a novel centrosome-related prognostic signature that accurately predicts OS in LUAD and can assist in clinical diagnosis and treatment.

Indexed as

CentrosomeCRSLung adenocarcinomaPrognostic modelTumor microenvironment

Identifiers

PMID39592523
PMCPMC11599701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.